A Phase 2 interventional study of parenteral nutrition in Cancer Cachexia and Pancreatic Cancer, sponsored by CONKO-Studiengruppe. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-06-12.
Sponsored by CONKO-Studiengruppe · Phase 2, Interventional, and Supportive care
The purpose of this study is to determine whether the additional nutrition support is improving the nutritional status of patients suffering cancer caxechia or not.
To examine the impact of additional parenteral nutrition (APN) we prospective evaluated 32 pts suffering APC and progressive cachexia. This assay is based on a bioelectrical impedance analysis (BIA) as a proven tool for nutritional investigation in patients with chronic disease. Phase angle, determined by BIA, has been found to be a prognostic indicator in several chronic and malignant conditions, such as HIV, liver cirrhosis, chronic obstructive pulmonary disease lung cancer and pancreatic cancer.
3,235 studies on the registry are indexed under Pancreatic Neoplasms; 899 are open to participants now.
This study's enrollment of 32 is below the median of 46 across 2,424 interventional studies indexed under Pancreatic Neoplasms.
Browse Pancreatic Neoplasms studies →CONKO-Studiengruppe is the lead sponsor of 6 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
25kcal/kg/bw /day via parenteral support
Dietary Supplement: parenteral nutrition
25kcal/kg bw with parenteral nutrition
Also known as: no specific brand name
nutritional status presented by phase angle
Time frame: 12 weeks
quantity of port infections, quantity of oedema, quantity of diarrhea
Time frame: 12 weeks
This study is completed, as verified in Jun 2009. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CONKO-Studiengruppe